US medicines with clinical-trial evidence for a new indication
52 of the 953 medicines with a UsTxGNN report have a TxGNN-predicted new indication graded at evidence level L1 or L2 (14 at L1, 38 at L2), meaning clinical-trial evidence (randomized trials, Phase 2–3 trials or systematic reviews) was found for it.
The medicines come from the FDA National Drug Code (NDC) Directory, with marketing status from Drugs@FDA shown in each drug report; the list reflects the drug reports as last updated on 2026-11-20.
Trial evidence for a predicted indication is not proof of efficacy. Every candidate below still requires clinical validation and regulatory review before any clinical use.
Medicines with trial evidence (L1–L2)
| Drug | Predicted new indication | Evidence level | Registered trials cited (NCT) |
|---|---|---|---|
| Bendamustine | mantle cell lymphoma | L1 | 10 |
| Bromfenac | Eye disease | L1 | 10 |
| Bupropion | Attention deficit-hyperactivity disorder | L1 | 6 |
| Busulfan | Myelodysplastic syndrome | L1 | 10 |
| Clofarabine | myeloid leukemia | L1 | 10 |
| Clomipramine | Anxiety disorder | L1 (with caveat) | 8 |
| Dapsone | Pneumocystosis | L1 | 10 |
| Nepafenac | Eye disease | L1 | 11 |
| Peginterferon Alfa-2A | Hepatitis E virus infection | L1 | 10 |
| Platinum | Urinary bladder carcinoma | L1 (with caveat) | 6 |
| Polidocanol | Esophageal varices with bleeding | L1 (with caveat) | 0 |
| Potassium | Hypertensive disorder | L1 (with caveat) | 7 |
| Ribavirin | Chronic hepatitis B virus infection | L1 (with caveat) | 10 |
| Tacrolimus | Seborrheic dermatitis | L1 | 2 |
| Acetylcysteine | thrombotic disease | L2 | 7 |
| Armodafinil | insomnia (disease) | L2 | 3 |
| Atorvastatin | HIV infectious disease | L2 | 10 |
| Belinostat | Myeloid leukemia | L2 (with caveat) | 6 |
| Brentuximab Vedotin | Follicular lymphoma | L2 (with caveat) | 6 |
| Cefprozil | urinary tract infection (disease) | L2 | 0 |
| Citalopram | Obsessive-compulsive disorder | L2 | 4 |
| Clozapine | Manic bipolar affective disorder | L2 | 1 |
| Cyclobenzaprine | Myofascial pain syndrome | L2 (with caveat) | 10 |
| Dasatinib | Ewing sarcoma | L2 (with caveat) | 2 |
| Diazepam | Insomnia (disease) | L2 | 0 |
| Docetaxel | Ewing sarcoma | L2 | 8 |
| Doxorubicin | Ewing sarcoma | L2 | 10 |
| Eslicarbazepine | Migraine disorder | L2 (with caveat) | 1 |
| Fludarabine | Plasma cell myeloma | L2 | 10 |
| Goserelin | Amenorrhea | L2 | 1 |
| Hydrocortisone | Alopecia areata | L2 | 1 |
| Idelalisib | Mantle cell lymphoma | L2 (with caveat) | 5 |
| Ketamine | Headache disorder | L2 (with caveat) | 9 |
| Lenalidomide | Myeloid leukemia | L2 | 12 |
| Mefenamic Acid | Headache disorder | L2 | 0 |
| Montelukast | Bronchitis | L2 | 10 |
| Mycophenolate Mofetil | HIV infectious disease | L2 (with caveat) | 4 |
| Nortriptyline | Attention deficit-hyperactivity disorder | L2 (with caveat) | 0 |
| Ofatumumab | Follicular lymphoma | L2 | 10 |
| Oxaliplatin | Malignant pleural mesothelioma | L2 | 3 |
| Pazopanib | Liposarcoma | L2 | 6 |
| Pimecrolimus | Seborrheic dermatitis | L2 | 1 |
| Prednisolone | Alopecia areata | L2 | 0 |
| Propofol | Migraine disorder | L2 | 3 |
| Regorafenib | Liposarcoma | L2 | 1 |
| Risankizumab | Dermatitis | L2 | 2 |
| Sodium Oxybate | Insomnia (disease) | L2 | 3 |
| Sofosbuvir | Top TxGNN prediction: hepatitis B virus infection (rank 1). Best-supported candidate after evidence review: hepatitis E virus infection (rank 2) | L2 (with caveat) | 5 |
| Solriamfetol | Attention deficit-hyperactivity disorder | L2 | 5 |
| Sucralfate | Duodenogastric reflux | L2 | 0 |
| Tizanidine | Migraine disorder | L2 | 1 |
| Ustekinumab | Dermatitis | L2 | 6 |
How to read this list
- Evidence level follows the site’s criteria: L1 = Multiple Phase 3 RCTs / systematic reviews; L2 = Single RCT or multiple Phase 2 trials. “(with caveat)” means the drug report qualifies the grade; read the note in the report before relying on it.
- Predicted new indication is the main prediction shown in each drug report. Indications and contraindications already recorded in the TxGNN knowledge graph are excluded, but some predictions may still overlap an established use; the report explains this where it applies.
- Registered trials cited counts the ClinicalTrials.gov (NCT) numbers cited in the drug report. Reports cite a selection of the trials found; 0 means the report cites no registered trial, and its literature evidence section shows the basis for the grade.
- For all levels and the full method, see High Evidence (L1-L2), All Drugs and the methodology.
Disclaimer
This report is for academic research reference only and does not constitute medical advice. Always follow your physician's instructions; never adjust medication on your own. Any drug repurposing decision requires full clinical validation and regulatory review.
Reviewed by: 藥提醒科技有限公司 (yao.care)
This report is for academic research reference only and does not constitute medical advice. Always follow your physician's instructions; never adjust medication on your own. Any drug repurposing decision requires full clinical validation and regulatory review.
Reviewed by: 藥提醒科技有限公司 (yao.care)